EP0082461B1 - Substituierte Phenoxyalkanolamine und Phenoxyalkanol-cycloalkylamine, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zubereitungen und Zwischenprodukte - Google Patents

Substituierte Phenoxyalkanolamine und Phenoxyalkanol-cycloalkylamine, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zubereitungen und Zwischenprodukte Download PDF

Info

Publication number
EP0082461B1
EP0082461B1 EP82111565A EP82111565A EP0082461B1 EP 0082461 B1 EP0082461 B1 EP 0082461B1 EP 82111565 A EP82111565 A EP 82111565A EP 82111565 A EP82111565 A EP 82111565A EP 0082461 B1 EP0082461 B1 EP 0082461B1
Authority
EP
European Patent Office
Prior art keywords
general formula
group
carbon atoms
phenoxyalkanol
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
EP82111565A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0082461A3 (en
EP0082461A2 (de
Inventor
Erich Dr. Dipl.-Chem. Cohnen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Priority to AT82111565T priority Critical patent/ATE25667T1/de
Publication of EP0082461A2 publication Critical patent/EP0082461A2/de
Publication of EP0082461A3 publication Critical patent/EP0082461A3/de
Application granted granted Critical
Publication of EP0082461B1 publication Critical patent/EP0082461B1/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/32—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups bound to acyclic carbon atoms and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/33—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups or etherified hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C47/00—Compounds having —CHO groups
    • C07C47/20—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms
    • C07C47/277—Unsaturated compounds having —CHO groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups

Definitions

  • the intermediates of formula II also have therapeutic properties.
  • they can be used like the end products of the general formula according to the invention.
  • the new compounds of general formulas I and II contain one or two asymmetric carbon atoms.
  • the various optical isomers and the diastereoisomers are therefore also a subject of the invention, as are the addition salts of these compounds with acids. Racemates can be separated into their optical antipodes by methods known per se, for example by using optically active acids such as tartaric acid, camphor sulfonic acid or dibenzoyl tartaric acid, or as an ester or ether with optically active components or via urea inclusion compounds.
  • alkyls R 1 , R 2 , R 3 , R 4 and R 5 and the alkyl radicals of the acyl group R 3 means both straight-chain and branched-chain aliphatic hydrocarbon radicals containing 1 to 6 carbon atoms, such as, for example, the methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, sec.-butyl group, isobutyl group, tert.-butyl group, n-pentyl group, isopentyl group, neopentyl group, amyl group, n-hexyl group, isohexyl groups and the branched hexyl groups with quaternary carbon atom, this definition being the Alkyl groups R 1 , R 2 and R 4 refer to alkyls with up to four carbon atoms.
  • the methyl group, the ethyl group and the propyl groups are particularly preferred
  • R 4 is preferably methyl, ethyl, isopropyl or cyclopropylmethyl.
  • Preferred acyl groups are alkanoyl groups with 1 to 6 carbon atoms, in particular the formyl group, the acetyl group and the propionyl groups.
  • the radical R 5 is preferably in the 2 position of the phenyl group or in the ortho position to the 2-hydroxy-3-aminoalkoxy side chain.
  • the halogen radical R 5 is fluorine, chlorine, bromine or iodine, but especially chlorine or bromine.
  • the preferred alkyl radicals R 5 are methyl and ethyl.
  • R 5 is preferably also hydrogen.
  • R 1 and R 2 together mean the alkylidene groups - (CH 2 ) n -, in which n is 4 or 5, contain a cyclopentane ring or cyclohexane ring. With this definition, they are formed with the inclusion of the a-carbon atom of the propoxy side chain.
  • R 1 and R 2 are alkyl, in particular methyl and also compounds in which R 1 and R 2 are alkyl, in particular methyl groups and R 4 is methyl or cyclopropylmethyl.
  • novel compounds of general formula I and their acid addition salts according to the invention have valuable therapeutic properties. They are characterized by a cardioselective ⁇ 1 - adrenolytic effect and hypotensive properties and are particularly suitable for the treatment of angina pectoris, hypertension and cardiac arrhythmias. They are also suitable for treating glaucoma because they lower the intraocular pressure.
  • the surprisingly high cardioselectivity of the new compounds depends, among other things, on the di-substitution of the a-carbon atom of the propoxy chain.
  • Compounds in which R 3 represents a hydrogen atom have proven to be particularly valuable.
  • R 1 and R 2 are then preferably alkyl groups as indicated, in particular methyl groups.
  • the compounds of the present invention can be administered orally or parenterally in humans in a dosage of 20 mg to 1 g, preferably 50 mg to 500 mg, per day, in particular in divided doses, for example two or three times a day.
  • ED25 i. v. Reduces isoprenaline-related tachycardia in cats by 25% (ED25).
  • this dose is 1.75 mg.
  • the daily dose has to be adjusted individually because it depends on the receptor sensitivity and the sympathetic tone of the patient.
  • the treatment is expediently started with low doses and then increased.
  • doses of 50 to 200 mg, divided into two or three doses are preferably administered daily.
  • Angina pectoris is preferably treated with 50 to 200 mg per day, divided into two doses.
  • 200 to 400 mg daily, divided into two or three doses are administered.
  • aqueous isotonic solutions in doses of one or more drops are applied locally to the eye one or more times a day.
  • compositions which contain a compound of the formula or its pharmaceutically acceptable salts, together with a pharmaceutically acceptable diluent or carrier.
  • the compounds according to the invention can be mixed with customary pharmaceutically acceptable diluents or carriers and, if appropriate, with other auxiliaries and administered, for example, orally or parenterally.
  • You can take orally in the form of tablets, coated tablets, syrups, Suspensions and liquids, or administered parenterally in the form of solutions or suspensions.
  • Preparations to be administered orally can contain one or more additives, such as sweeteners, flavoring agents, colorants and preservatives.
  • Tablets can contain the active ingredient mixed with customary, pharmaceutically compatible auxiliaries, for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin , Lubricants such as magnesium stearate, stearic acid and talc.
  • auxiliaries for example inert diluents such as calcium carbonate, sodium carbonate, lactose and talc, granulating agents and agents which promote the disintegration of the tablets when administered orally, such as starch or alginic acid, binders such as starch or gelatin , Lubricants such as magnesium stearate, stearic acid and talc.
  • Suitable carriers are, for example, milk sugar (lactose), gelatin, corn starch, stearic acid, ethanol, propylene glycol, ether of tetrahydrofuryl alcohol and water.
  • the tablets can be coated according to known procedures to delay disintegration and absorption in the gastrointestinal tract, whereby the activity of the active ingredient can extend over a longer period of time.
  • the active ingredient can be mixed in the suspensions with auxiliaries which are customary for the preparation of such compositions, for example suspending agents such as methyl cellulose, tragacanth or sodium alginate, wetting agents such as lecithin, polyethylene stearate and polyoxyethylene sorbitan monooleate, and preservatives such as ethyl parahydroxybenzoate.
  • suspending agents such as methyl cellulose, tragacanth or sodium alginate
  • wetting agents such as lecithin, polyethylene stearate and polyoxyethylene sorbitan monooleate
  • preservatives such as ethyl parahydroxybenzoate.
  • Capsules can contain the active ingredient as a single component or mixed with a solid diluent such as calcium carbonate, calcium phosphate or kaolin.
  • the injectable preparations are also formulated in a manner known per se.
  • the pharmaceutical preparations can contain the active ingredient in an amount of 0.1 to 90%, in particular 1 to 90%, the rest being a carrier or additive.
  • Solid preparations such as tablets and capsules are preferred in view of manufacture and administration.
  • the preparations preferably contain the active ingredient in an amount of 50-100 mg.
  • the reduction takes place either with palladium-hydrogen in alcoholic solution in the presence of glacial acetic acid at 20 to 100 ° C and 5 to 10 bar or with zinc / hydrochloric acid at temperatures between 50 and 70 ° C.
  • the amino group is alkylated either with an alkylating agent such as, for example, dialkyl sulfate or tosyl alkyl ester, or by reaction with an aldehyde and subsequent reduction of the azomethine with a borohydride.
  • an alkylating agent such as, for example, dialkyl sulfate or tosyl alkyl ester
  • the acyl groups are introduced with appropriate carboxylic acid anhydrides or carboxylic acid chlorides in the presence of a basic catalyst or by heating the components.
  • the acyl esters which may be formed are cleaved by alkaline hydrolysis.
  • nitroalkanes or nitrocyclopentane and nitrocyclohexane of the formula IV are condensed with the aldehyde of the formula III in alcoholic solution in the presence of sodium alcoholate at room temperature.
  • nitro compounds of the formula IV are known or can be obtained by known processes.
  • the compounds of formula III are particularly accessible from compounds of general formula V by oxidative cleavage with lead (IV) acetate in ethyl acetate, benzene, toluene or sodium metaperiodate in alcohol / water mixtures.
  • the compounds of formula V used as starting materials are new compounds. They can be prepared from the corresponding known phenols by reaction with 2,3-epoxypropanol with catalytic amounts of a quaternary amine in a solvent or by directly melting the reactants together at temperatures between 120 and 160 ° C. They are valuable intermediates in the production of the end products according to the invention.
  • the compounds of general formula 1 can be isolated from the reaction mixtures either as bases or in the form of their salts.
  • Suitable inorganic acids are, for example, hydrohalic acids, for example hydrochloric acid or sulfuric acid, and organic acids, for example fumaric acid and maleic acid.
  • hydrohalic acids for example hydrochloric acid or sulfuric acid
  • organic acids for example fumaric acid and maleic acid.
  • a solution of 2.5 g of sodium metaperiodate in 100 ml of water and 13 ml of 0.1 N boric acid is added dropwise to 12 g of the above diol in 100 ml of ethanol at 10-15 ° C. After one hour the NaJ0 3 is filtered off, the filtrate diluted with water and the aldehyde extracted with CHCI 3 . After evaporation of the solvent, 11 g of 4- (2-methoxy-ethyl) -phenoxy-acetaldehyde remain as mono-ethyl acetal.
  • Tablets containing the ingredients listed below are made according to known procedures. These are suitable for the treatment of hypertension in a dose of 50 mg twice a day, for the treatment of angina pectoris with a quantity of 50 mg twice a day and for the treatment of arrhythmias with a quantity of three times 100 mg daily.
  • Eye drops containing the following components can be prepared in a known manner. They can be used in a dose of one to two drops per eye once or twice a day, preferably one drop twice a day:

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP82111565A 1981-12-23 1982-12-14 Substituierte Phenoxyalkanolamine und Phenoxyalkanol-cycloalkylamine, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zubereitungen und Zwischenprodukte Expired EP0082461B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT82111565T ATE25667T1 (de) 1981-12-23 1982-12-14 Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3151201 1981-12-23
DE19813151201 DE3151201A1 (de) 1981-12-23 1981-12-23 Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte

Publications (3)

Publication Number Publication Date
EP0082461A2 EP0082461A2 (de) 1983-06-29
EP0082461A3 EP0082461A3 (en) 1983-09-28
EP0082461B1 true EP0082461B1 (de) 1987-03-04

Family

ID=6149614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP82111565A Expired EP0082461B1 (de) 1981-12-23 1982-12-14 Substituierte Phenoxyalkanolamine und Phenoxyalkanol-cycloalkylamine, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zubereitungen und Zwischenprodukte

Country Status (6)

Country Link
US (2) US4864061A (enrdf_load_stackoverflow)
EP (1) EP0082461B1 (enrdf_load_stackoverflow)
JP (1) JPS58116434A (enrdf_load_stackoverflow)
AT (1) ATE25667T1 (enrdf_load_stackoverflow)
CA (1) CA1188324A (enrdf_load_stackoverflow)
DE (2) DE3151201A1 (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte
US4745222A (en) * 1983-05-25 1988-05-17 Merrell Dow Pharmaceuticals Inc. Novel aryloxycycloalkanolaminoalkylene aryl ketones
NZ208230A (en) * 1983-05-25 1989-07-27 Merrell Dow Pharma Aryloxycycloalkanolaminoalkylenearyl (heteroaryl) ketones and pharmaceutical compositions
JPS60153826A (ja) * 1984-01-24 1985-08-13 松下電器産業株式会社 ハンドミキサ−
US4665094A (en) * 1985-08-29 1987-05-12 Merck & Co., Inc. Oculoselective beta-blockers for treatment of elevated intraocular pressure
US4945182A (en) * 1985-12-24 1990-07-31 Merck & Co., Inc. Oculoselective beta-blockers
JPH0794420B2 (ja) * 1988-08-30 1995-10-11 宇部興産株式会社 置換フェノキシアセトアルデヒドオキシム類の製造方法
US5068451A (en) * 1990-05-04 1991-11-26 National Science Council Production of 3-phenoxy propanal derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL301580A (enrdf_load_stackoverflow) * 1962-12-11
GB1301111A (en) * 1969-05-08 1972-12-29 Girling Ltd Two pedal hydraulic braking system
SE354851B (enrdf_load_stackoverflow) * 1970-02-18 1973-03-26 Haessle Ab
FR2139740A1 (en) * 1971-06-03 1973-01-12 Roussel Uclaf 1-amino-3-methyl-3-phenoxy-2-butanols - inhibitors of platelet stickiness for treatment of thrombosis
US4145442A (en) * 1972-04-04 1979-03-20 Aktiebolaget Hassle Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
ZA754241B (en) * 1974-11-01 1976-06-30 Haessle Ab New amines
FR2330383A1 (fr) * 1975-11-06 1977-06-03 Synthelabo Nouveaux ethers de phenols substitues, leurs sels, leur preparation et les medicaments qui les renferment
DE2645710C2 (de) * 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4243681A (en) * 1977-10-11 1981-01-06 Mead Johnson & Company Alkylthiophenoxypropanolamines and pharmaceutical compositions and uses thereof
US4342783A (en) * 1980-06-30 1982-08-03 Synthelabo Anti-glaucoma agent
US4402976A (en) * 1981-04-24 1983-09-06 E. R. Squibb & Sons, Inc. Method for treating glaucoma with systemic nadolol compositions
DE3125636A1 (de) * 1981-06-30 1983-01-13 Merck Patent Gmbh, 6100 Darmstadt 1-(p-2-isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol zur senkung des augeninnendrucks und ophtalmikum, enthalten diese verbindung
FR2512443A1 (fr) * 1981-09-10 1983-03-11 Synthelabo Derives de phenoxy-3 propanol-2, leur preparation et leur application en therapeutique
DE3151201A1 (de) * 1981-12-23 1983-07-28 Beiersdorf Ag, 2000 Hamburg Substituierte phenoxyalkanolamine und phenoxyalkanol-cycloalkylamine, verfahren zu ihrer herstellung, diese verbindungen enthaltende pharmazeutische zubereitungen und zwischenprodukte

Also Published As

Publication number Publication date
DE3275541D1 (en) 1987-04-09
JPH0316944B2 (enrdf_load_stackoverflow) 1991-03-06
ATE25667T1 (de) 1987-03-15
EP0082461A3 (en) 1983-09-28
US4871775A (en) 1989-10-03
DE3151201A1 (de) 1983-07-28
CA1188324A (en) 1985-06-04
JPS58116434A (ja) 1983-07-11
EP0082461A2 (de) 1983-06-29
US4864061A (en) 1989-09-05

Similar Documents

Publication Publication Date Title
EP0084164B1 (de) Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue bicyclische Aminosäuren als Zwischenstufen und Verfahren zu deren Herstellung
DE2733868C2 (de) Neue 1,2,4,5-Tetrahydro-3H-2-benzazepin-3-one, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
EP0026848B1 (de) Tetralinderivate, ihre Herstellung und Heilmittel, welche diese Verbindungen enthalten
EP0090362A2 (de) Neue Derivate von Cycloalka(c)pyrrol-carbonsäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung sowie neue Cycloalka(c)pyrrol-carbonsäuren als Zwischenstufen und Verfahren zu deren Herstellung
DE1493955A1 (de) Verfahren zur Herstellung substituierter Sulfonanilide
DE2143204C3 (de) N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
EP0148440A1 (de) 1,3,4,5-Tetrahydrobenz[c,d]indole, ein Verfahren zu ihrer Herstellung und ihre Verwendung
DE2108954A1 (en) 2-(furylmethyl)-6,7-benzomorphans - useful as cns active agents
EP0271013B1 (de) Basisch substituierte Phenylacetonitrile, ihre Herstellung und diese enthaltende Arzneimittel
AT368125B (de) Verfahren zur herstellung von neuen 9-aminoalkyl- fluorenen und von deren salzen
EP0082461B1 (de) Substituierte Phenoxyalkanolamine und Phenoxyalkanol-cycloalkylamine, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zubereitungen und Zwischenprodukte
EP0033156B1 (de) 1-Phenyl-2-cyclohexen-1-alkylamin-Derivate, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE69002474T2 (de) Carboxyalkyl-ether von 2-Amino-7-hydroxytetralin.
CH550768A (de) Verfahren zur herstellung neuer bis((4-hydroxy-3-hydroxymethylphenyl)aethanol)diamin-derivate.
EP0072960B1 (de) 1,5-Diphenylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0065295A1 (de) Substituierte Tryptaminderivate von Thienyloxypropanolaminen, Verfahren zu ihrer Herstellung, pharmazeutische Präparate auf Basis dieser Verbindungen sowie ihre Verwendung
EP0030380A1 (de) 2,3-Indoldionderivate, Verfahren zu ihrer Herstellung, Zwischenprodukte, Arzneimittel enthaltend solche 2,3-Indoldionderivate und ihre pharmazeutische Verwendung
CH636076A5 (de) Benzylalkoholderivate und verfahren zu deren herstellung.
EP0027928B1 (de) Piperidinderivate von 4,5-Dialkyl-3-hydroxy-pyrrol-2-carbonsäureestern, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen
DE2748466A1 (de) 4a-aryloctahydro-1h-2-pyrindine
EP0175249A2 (de) Neue Phenyl-acetonitril-Derivate
EP0006458B1 (de) Neue N1-Benzoyl-N2-phenyl-1,3-diaminopropan-2-ole und ihre Salze; Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0293716A2 (de) Polyhydrobenz(c,d)indolsulfonamide
DE3014738C2 (enrdf_load_stackoverflow)
EP0037062B1 (de) Substituierte 3-Aryl-2-cycloalken-1-one, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19821214

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 25667

Country of ref document: AT

Date of ref document: 19870315

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3275541

Country of ref document: DE

Date of ref document: 19870409

ITF It: translation for a ep patent filed
ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19871231

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19891007

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19891020

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19891025

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19891115

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19891127

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19891212

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19891213

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19891231

Year of fee payment: 8

Ref country code: GB

Payment date: 19891231

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Effective date: 19901214

Ref country code: AT

Effective date: 19901214

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19901215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19901231

Ref country code: CH

Effective date: 19901231

Ref country code: BE

Effective date: 19901231

BERE Be: lapsed

Owner name: BEIERSDORF A.G.

Effective date: 19901231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19910701

GBPC Gb: european patent ceased through non-payment of renewal fee
NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19910830

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19910903

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 82111565.6

Effective date: 19910910